Abstract
Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have